164 results
Page 2 of 9
6-K
EX-99
htghv
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
du48tw6b b5p
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
apwhd7qjesgu
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
xkmop
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-1
jbbfhu0mu1 0q
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
EX-99
8hi6f i1dgd5c30swj4
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
aocxe6aa da4l36
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
wfb9u1j
10 Nov 22
Current report (foreign)
7:08am
6-K
EX-99
wu5uxst9o1
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am
6-K
EX-99
zumj7 6u1tr8m7
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
6-K
EX-10.1
o9awry08g ri
21 Sep 22
Current report (foreign)
8:00am
424B5
udghf4il6 tdutm9i0i
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
22bg8zeb30jx
15 Sep 22
Current report (foreign)
8:39am
6-K
EX-99
sg6ky8x ho
12 Sep 22
BioLineRx Announces Submission of New Drug Application
8:16am
6-K
EX-99
44k2i7fw2rz21 3a8
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
pmbetcb tn9qcfa0adp6
28 Jun 22
BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in
7:14am
6-K
EX-99
6g6xt8
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-99
dna 3w70zhj
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am